Sequencing Method that Maps Breast Cell Differentiation Provides Insight to Cancer Development – Clinical OMICs News

Salk Institute researchers have used of a state-of-the-art technology known as single-nucleus (sn) assay for transposase-accessible chromatin (ATAC) sequencing (snATAC-seq) to profile how specific types of mammary cells differentiate during development. The findings, published in Cell Reports, provide new insights into normal breast development, and could ultimately point to new therapeutic strategies for different subtypes of breast cancer. The researchers have also made their findings available through a free online resource.

In order to understand what goes wrong in breast cancer, we need to first understand how normal development works, said research lead Geoffrey Wahl, PhD, a professor in the Gene Expression Laboratory. This study represents a major step in that direction, as we were able to profile each cell during breast development. We expect this information to be a valuable hypothesis-generating resource for the mammary gland community. The teams work is published in a paper titled, Single-Cell Chromatin Analysis of Mammary Gland Development Reveals Cell-State Transcriptional Regulators and Lineage Relationships.

The specialized functions of different tissues result from the coordinated activities of diverse cell types that develop from progenitor cells, the authors explained. The process of cell differentiation into these specialized types is controlled through mechanisms including epigenetics. The epigenetic programming of stem cells enables them to either retain their multi-potentiality or differentiate into the specific cell types. Defining how epigenetic and molecular mechanisms are involved in orchestrating developmental plasticity and the differentiation of different cell types and their functions is important to help our understanding of processes that underlie tissue development and repair after injury, but also potentially how the activation of cancer genes can impact on these processes and drive cancer progression.

As the team pointed out, The mammary gland is an excellent system for studying mechanisms of cellular specification because of its accessibility; the dramatic changes it undergoes in embryogenesis and postnatal development in response to puberty, pregnancy, and involution; and the substantial knowledge gained about factors involved in these cell-state transitions.

Mature breast tissue contains two main cell types, which may be involved in breast cancer. Luminal cells line the ducts and produce milk, while the surrounding basal cells contract to move the milk through and out of the ducts. The Salk Institute scientists were interested in what drives the molecular changes that govern how, during development, stem cells become specialized into these types of cells. To investigate at the level of individual cells they used sn(ATAC)-seq profiling of both fetal and adult mammary cells to investigate how changes in DNA packaging into chromatin impact on whether certain genes are either accessible or inaccessible, which can then affect gene expression and the development of these different cell types.

We sought to obtain a molecular map of these developing breast cells to better understand how breast tissues are formed during development and maintained during adulthood, noted co-first author and staff scientist Christopher Dravis. By examining differences in chromatin accessibility, we aimed to understand which regions of the genome affected transcription, the process that involves making RNA from DNA, and how that affected cell development, added co-first author Zhibo Ma, Ph.D.

The researchers used the single-cell profiling technique to compare chromatin accessibility in adult mouse breast tissue with that in breast tissue at the late prenatal development stage. They separated the prenatal cells into groups with basal-like and luminal-like features, based on chromatin accessibility. The results, surprisingly, suggested that even before birth the individual cells were already poised to become either a basal cell or luminal cell. fetal cells at this stage of mammary development are starting to acquire adult-like chromatin accessibility, but they still largely possess their fetal-specific features, the scientists commented. The findings suggested that most cells at the late prenatal stage are weakly committed and biased toward either a luminal or basal fate, and that this likely positions these cells to differentiate rapidly into the respective cell type in response to appropriate microenvironmental cues after birth. It is then possible that abnormal changes to these processes may lead to tumor development later on.

The team also used bioinformatics and machine learning techniques to analyze different developing cell features, which highlighted a complex picture of breast development and maturation that could help research teams better understand the mechanisms that control breast tissue. The data and strategies described provide a resource for future epigenetic studies of mammary cell regulation, a catalog of upstream control elements containing binding sites for cell-state-determining transcription factors, computational approaches that provide finer distinction of mammary cell states, and a pseudo time progression of mammary differentiation, the investigators stated.

The Salk scientists have integrated their findings into a free online database, detailed in their paper, to help inform continuing research into cell growth, gene regulation, and other factors across multiple cell types and developmental states. The authors believe the databasewhich allows for comparison between chromatin accessibility and gene expression during normal breast development, among other componentscould be used to improve our understanding of how breast cells become cancerous. Our chromatin profiling of individual mammary cells at embryonic and adult developmental stages, and accompanying analyses that predict transcription factor activity and gene accessibility in relation to distinct mammary cell states, provide valuable resources to discover and validate cell-state regulators, they wrote. The links between mammary development and breast cancer suggest that this resource, which we have made available as a web-based app, will have significant utility in target discovery for breast cancers.

My objective has always been to help people with cancer and, by disseminating research as widely and as quickly as possible, we hope to accelerate research advancement and therapy development, said Wahl, who holds the Daniel and Martina Lewis Chair. This study has provided us with a concrete way of understanding the steps involved in mammary development and reveals a complexity that was not evident by most other methods. We are excited to share this with the broader research community.

The authors plan to add data from more developmental time points to further develop the database of how cancer develops, with a goal of informing the development of more effective therapies.

Link:
Sequencing Method that Maps Breast Cell Differentiation Provides Insight to Cancer Development - Clinical OMICs News

The 2019 Nobel Prize in Medicine awarded for research in cellular responses to oxygen – World Socialist Web Site

The 2019 Nobel Prize in Medicine awarded for research in cellular responses to oxygen By Benjamin Mateus 10 October 2019

In the course of a lifetime, the human heart will beat more than three billion times. We will have taken more than 670 million breaths before we reach the end of our lives. Yet, these critical events remain unconscious and imperceptible in everyday life, unless we exert ourselves, such as running up several flights of stairs. We quickly tire, stop to take deep breaths and become flushed.

With the deepening comprehension by medical science of how our bodies work, we have come to better understand the fundamental importance of oxygen to life. Every living organism relies on it in one form or another. However, how cells and tissues can monitor and respond to oxygen levels remained difficult to elucidate. It has only been late in the 20th century with advances in cellular biology and scientific instrumentation that these processes have finally been explained.

On Monday, the 2019 Nobel Prize in Physiology or Medicine was awarded jointly to three individuals: William G. Kaelin, Jr., Sir Peter J. Ratcliffe, and Gregg L. Semenza. Specifically, their discoveries helped elucidate the mechanisms for lifes most basic physiologic processes.

They were able to discover how oxygen levels directly affect cellular metabolism, which ultimately controls physiological functions. More importantly, their findings have significant implications for the treatments of conditions as varied as chronic low blood counts, kidney disease, patients with heart attacks or stroke and cancers. One of the hallmarks of cancer is its ability to generate new blood vessels to help sustain its growth. It also uses these oxygen cellular mechanisms to survive in low oxygen environments.

Dr. William G. Kaelin Jr. is a professor of medicine at Harvard University and the Dana-Farber Cancer Institute. The main focus of his work is on studying how mutations in what are called tumor suppressor genes lead to cancer development. Tumor suppressor genes are special segments of the DNA whose function is to check the integrity of the DNA before allowing a copy of itself to be made and undergo cell division, which prevents cells from propagating errors. Cellular mechanisms are then recruited to fix these errors or drive the cell to destroy itself if the damage is too severe or irreparable.

His interest in a rare genetic disorder called Von Hippel-Lindau disease (VHL) led him to discover that cancer cells that lacked the VHL gene expressed abnormally high levels of hypoxia-regulated genes. The protein called the Hypoxia-Inducible Factor (HIF) complex was first discovered in 1995 by Gregg L. Semenza, a co-recipient of the Nobel Prize. This complex is nearly ubiquitous to all oxygen-breathing species.

The function of the HIF complex in a condition of low oxygen concentration is to keep cells from dividing and growing, placing them in a state of rest. However, it also signals the formation of blood vessels, which is important in wound healing as well as promoting the growth of blood vessels in developing embryos. In cancer cells, the HIF complex helps stimulate a process called angiogenesis, the formation of new blood vessels, which allows the cancer cells to access nutrition and process their metabolic waste, aiding in their growth. When the VHL gene is reintroduced back into the cancer cells, the activity of the hypoxia-regulated genes returns to normal.

Dr. Gregg L. Semenza is the founding director of the vascular program at the Johns Hopkins Institute for Cell Engineering. He completed his residency in pediatrics at Duke University Hospital and followed this with a postdoctoral fellowship at Johns Hopkins. His research in biologic adaptations to low oxygen levels led him to study how the production of erythropoietin (EPO) was controlled by oxygen. EPO is a hormone secreted by our kidneys in response to anemia. The secretion of EPO signals our bone marrow to produce more red blood cells.

His cellular and mouse model studies identified a specific DNA segment located next to the EPO gene that seemed to mediate the production of EPO under conditions of low oxygen concentration. He called this DNA segment HIF.

Sir Peter J. Ratcliffe, a physician and scientist, trained as a nephrologist, was head of the Nuffield Department of Clinical Medicine at the University of Oxford until 2016, when he became Clinical Research Director at the Francis Crick Institute. Through his research on the cellular mechanisms of EPO and its interaction between the kidneys and red cell production, he found that these mechanisms for cellular detection of hypoxia, a state of low oxygen concentration, were also present in several other organs such as the spleen and brain. Virtually all tissues could sense oxygen in their micro-environment, and they could be modified to give them oxygen-sensing capabilities.

Dr. Kaelins findings had shown that the protein made by the VHL gene was somehow involved in controlling the response to low oxygen concentrations. Dr. Ratcliffe and his group made the connection through their discovery that the protein made by the VHL gene physically interacts with HIF complex, marking it for degradation at normal oxygen levels.

In 2001, both groups published similar findings that demonstrated cells under normal oxygen levels will attach a small molecular tag to the HIF complex that allows the VHL protein to recognize and bind HIF, marking it for degradation by enzymes. If the oxygen concentration is low, the HIF complex is protected from destruction. It begins to accumulate in the nucleus where it binds to a specific section of the DNA called hypoxia-regulating genes, which sets into motion the necessary mechanisms to respond to the low oxygen concentration.

The ability to sense oxygen plays a vital role in health and various disease states. Patients who suffer from chronic kidney failure also suffer from severe anemia because their ability to produce EPO is limited. This hormone is necessary for the stem cells in our bone marrow to produce red blood cells. Understanding how cancer cells utilize oxygen-sensing mechanisms has led to a variety of treatments that targets these pathways. The ability to elucidate these mechanisms offers insight into directions scientists and researchers can take to design or create novel treatments.

The WSWS recently published its 75,000th article. Become a monthly donor today and keep up this vital work. It only takes a minute. Thank you.

Go here to read the rest:
The 2019 Nobel Prize in Medicine awarded for research in cellular responses to oxygen - World Socialist Web Site

Translational Regenerative Medicine Market Estimated to Expand at a Robust CAGR over 2017 2025 – Online News Guru

Regenerative medicine is a segment of translational research in molecular biology and tissue engineering. It involves the process of regeneration of human cells, tissues, or organs to re-establish their normal functions through stimulation of bodys repair system. They are widely used in the treatment of many degenerative disorders occurring in the areas of dermatology, orthopedic, cardiovascular and neurodegenerative diseases. Stem cell therapy is the available tool in the field of translational regenerative medicine. It has gained importance in the past few years as it is a bio-based alternative to synthetic options. Stem cells have high power of regeneration. Hence, these enable production of other cells in the body. This has increased demand for stem cell therapy in the treatment of degenerative diseases. Currently, stem cell therapy has applications in the treatment of diseases such as autism, cancer, retinal diseases, heart failure, diabetes, rheumatoid arthritis, Alzheimers. Extensive research is being carried out on stem cell therapy. The Centre for Commercialization of Regenerative Medicine (CCRM) has reported around 1900 active clinical trials undergoing currently. It also reported 574 active industry-sponsored cell therapy clinical studies, 50 of these are in phase 3 development. Hence, stem cell therapy is projected to contribute to the growth of the translational regenerative medicine market. However, ethical issues in the use of embryonic stem cells is likely to restrain the market.

Rising prevalence of degenerative diseases, aging population, rapid growth of emerging countries, and technical advancements in developed countries are the major factors fueling the growth of the translational regenerative medicine market.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/translational-regenerative-medicine-market.html

The global translational regenerative medicine market has been segmented based on product type, therapy, application, and region. In terms of product type, the market has been categorized into cellular and acellular. The cellular segment dominated the global market in 2016. Based on therapy, the global translational regenerative market has been segmented into cell therapy, gene therapy, immunotherapy, and tissue engineering. Immunotherapy is projected to be the fastest growing segment during the forecast period. In terms of application, the market has been segmented into orthopedic & musculoskeletal, cardiology, diabetes, central nervous system diseases, dermatology, and others. Cardiology and orthopedic & musculoskeletal are anticipated to be the fastest growing segments of the global translational regenerative medicine market.In terms of region, the global translational regenerative medicine market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the global regenerative medicine market owing to a large number of leading companies and expansion of research and development activities in the U.S. Increased medical reimbursement and advanced health care also drive the market in the region. Orthopedic is the leading application segment contributing to the growth of the market in the region. Asia Pacific is forecasted the huge growth because of large consumer pool, rising income, and health care expenditure. However, the market in Asia Pacific could face challenges such as high cost of bio-based medicines and stringent regulatory policies.

The global translational regenerative medicine market is dominated by key players such as CONMED Corporation, Arthrex, Inc., Organogenesis, Inc., Nuvasive, Inc., Osiris Therapeutics, Inc., Celgene Corporation, Brainstorm Cell Therapeutics Inc. and Medtronic.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=30440&source=atm

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=30440&source=atm

Read the original post:
Translational Regenerative Medicine Market Estimated to Expand at a Robust CAGR over 2017 2025 - Online News Guru

Faculty Highlights: Recent Grants and Awards | Now – Drexel Now

In this section,Drexel Quarterlyprovides an update on research funding, commercialization activity and faculty honors at Drexel, courtesy of the Office of the Provost. This update offers a snapshot of activity during the most recent terms.

Major Gifts, Honors and Recognitions

Bang Jeon, PhD, professor of economics in the Scool of Economics in the LeBow College of Business, was awarded a Fulbright Scholarship to work and study in Romania at the Bucharest University of Economic Studies.

College of Engineering Dean and Distinguished Professor of Civil, Architectural and Environmental Engineering Sharon Walker, PhD, was elected to the Executive Council for the American Society of Engineering Educations Engineering Deans Institute. It is a highly visible group that leads the conversation around engineering in higher education and leadership within the community.

Christopher Wright, PhD, assistant professor in the School of Education, was named a 2019 recipient of the Presidential Early Career Award for Scientists and Engineers, which is the highest honor bestowed by the United States government to scientists and engineers at the start of their independent research careers who show promise for leadership in science and technology.

ReneeTurchi, MD, a clinical professor in the Department of Community Health and Prevention at the Dornsife School of Public Healthanddirector of the Maternal and Child Health Program, was named a 2019 Champion of Childrens HealthbyFamily Voices,a national organization that focuseson family-centered care for children.

John Medaglia, PhD, assistant professor of psychology in the College of Arts and Sciences,was selected as a fellow in thePsychonomicsSociety,a preeminent societyfor general scientific experimental psychology.

Elizabeth Kimball,PhD, assistant professor of English in theCollege of Arts and Sciences,was appointed to a three-year term as co-chair of the executive board of the Philadelphia Area Council of Writing Program Administrators, whichadvocates best practices in writing programs for the regionshigher education institutions.

Adam Knowles,PhD, assistant teaching professor of philosophy in the College of Arts and Sciences,received aresearchfellowshipto Germanyfrom the Andrew Mellon Foundation and the Volkswagen Foundation. Hell spend the 201920 academic yearat theGerman Literature Archive in Marbacham Neckar, Germany for his forthcoming book, Categories of Complicity: Philosophy Under National Socialism.

Michael Lane, PhD, associate professor of neurobiology and anatomy in the College of Medicine, received the 2019 Molly and BernardSanbergMemorial Award of the American Society for Neural Therapy and Repair in recognition of his significant contributionsin the field. The award is given only periodically.

SeenaAjit,PhD, associate professor ofpharmacology and physiology in the College of Medicine,has beenappointedto the Somatosensory & Pain Systems Study Section,National Institutes of Health, for a four-year term.

Patrick Osei-Owusu, PhD, associate professor of pharmacology and physiology in the College of Medicine,has beenappointed tothe Cardiac Contractility, Hypertrophy and Failure Study Section, Center for Scientific Review, National Institutes of Health, for a six-year term.

Erjia Yan, PhD, associate professor in the College of Computing & Informatics, was named the recipient of the 2019 EugeneGarfield Awardfor Innovation in Citation Analysis by the Web of Science Group, a Clarivate Analytics company.

The College of Engineerings Distinguished Professor Michel Barsoum, PhD, and Distinguished University and Charles T. and Ruth M. Bach Professor YuryGogotsi, PhD, were jointly awarded the 2020 International Ceramics Prize, the highest honor conferred by the World Academy of Ceramics that has only been bestowed upon 20 other scientists.

Cheryl A. Hanau, MD, professor and chair of pathology in the College of Medicine, received the 2019 Michele Raible Distinguished Teaching Award in Undergraduate Medical Education from the Association of Pathology Chairs for her outstanding contributions and her stature as a nationally recognized pathology educator.

Sponsored Research

Alex Ortega,PhD, professor and chair of the Department of Health Management and Policy at the Dornsife School of Public Health,was awarded a $3.2 million R01 grant by the National Institutes of Health to study psychiatric and substance use disorders among island Puerto Ricans impacted by Hurricane Maria.

Lin Han, PhD, associate professorinthe School of Biomedical Engineering, Science and Health Systems(PI), receiveda five-year $2.67 million NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD) R01 grant for the project titled,Mechanical Regulation of Cell Fate and Multi-Scale Function in the Developing Meniscus. Han also receiveda five-year $1.7millionNIH R01 Grant for the project titled, Biomechanics of Cartilage: Roles of Decorin in ECM Assembly and Degradation.

The School of Biomedical Engineering, Science and Health Systems Peter A. Lewin, PhD, Richard B. Beard University Professor and Director of the Biomedical Ultrasound Research and Education Center (PI); Leonid Zubkov, PhD, research professor; and Michael Neidrauer, PhD, assistant professor, andcolleaguesreceived a year-four $608,000NIH R01 renewal grant (grant total is $3millionfor 5 years) for the project titled, Enhanced Ultrasound Treatment of Chronic Wounds with Monitoring of Healing and Quality of Life Outcomes.

Brian Lee,PhD, associate professorintheDepartment of Epidemiology and Biostatistics at the Dornsife School of Public Health, along with an international team of investigators, was awarded a $1.7 million R01 grant by the National Institute of Neurological Disorders and Stroke to conduct a pharmacoepidemiology study of maternal antiepileptic medication use during pregnancy and risk of autism spectrum disorders.

The College of Engineerings Jin Wen, PhD, professor,and Simi Hoque, PhD, associate professor, both in the Department of Civil, Architectural, and Environmental Engineering, have been awarded an NSF grant of $243,717 for their project entitled Collaborative Research: AccelNet: An International Network of Networks for Well-being in the Built Environment.

DanielMarenda, PhD, associate professor of biology (PI), and Jennifer Stanford, PhD, associate professor of biology (Co-PI), both in the College of Arts and Sciences, were awarded a $1.3 million grant from the National Science Foundation for their project EpigeneticControl of Steroid Hormone Signaling in Axon Pruning.

JasonWeckstein, PhD, associate professor of biodiversity, earth and environmental science in the College of Arts and Sciences,was awarded a $913,000 grant from the National Science Foundation for his project ComparativeCophylogenomicsin a Highly Replicated System:TinamouLice.

IrwinChaiken, PhD, professor of biochemistry and molecular biology in the College of Medicine, has been awarded a highly competitive National Institutes of Health Shared Instrumentation Grant in the amount of $364,883 entitled BiacoreS200 Surface Plasmon Resonance Instrument for a Shared Resources Facility. The instrument will assist the College of Medicine in securing additional grants.

C. Virginia F.OHayer, PhD, clinical associate professorofpsychiatry,College of Medicine,received a three-year $960,000 grant from the BoomerEsiasonFoundation to fund her multi-site research project on the treatment of depression and anxiety in adults with cystic fibrosis, Acceptance and Commitment Therapy [ACT] vs Traditional Supportive Therapy for Adults With Cystic Fibrosis.

Dong Wang, PhD, assistant professorof neurobiology and anatomy,College of Medicine,wasawarded an R01 grantfor $388,680from the National Institute of Mental Health for A Raphe-Hippocampus Pathway for Regulation of Memory Specificity During Consolidation.

Jacqueline Barker, PhD, assistant professor of pharmacology and physiology in the College of Medicine, has been awarded a two-year R03 $167,000 grant from the National Institute on Drug Abuse for her project Alterations inCorticostriatalControl of Cocaine Seeking in HIV Infection.

MeganDetloff, PhD, assistant professor of neurobiology and anatomy in the College of Medicine, was awarded a two-year grant from the National Institutes of Health HEAL (Helping to End Addiction Long-term) Initiative.

Maureen Tang, PhD,assistantprofessorin the Department ofChemical and Biological Engineering in the College of Engineering, has been awarded a National Science Foundation grantin the amount of$250,276 for her project titled,Collaborative Research: Regulating homogeneous and heterogeneous mechanisms in six-electron water oxidation.

FeiLu, PhD, assistant professor in the Department of Electrical and Computer Engineering in the College of Engineering, has been awarded $500,000 for a two-year grant from the Advanced Research Projects Agency-Energy (ARPA-E) through the Building Reliable Electronics to Achieve Kilovolt Effective Ratings Safely (BREAKERS) program. The project is titled, Resonant Solid State Breaker Based on Wireless Coupling in MVDCSystems.

The Kauffman Foundation increaseditsgrant to AndreKurmann, PhD,associate professor of economics and the Deans Research Scholar in Economicsin theSchool of Economics in the LeBow College of Business, by $100,000. Kurmannwill receive $128,385 over 18 months tostudy trade and its effect on labor markets.

Laura N. Gitlin, PhD, distinguished University professor and dean of the College of Nursing and Health Professions, was awarded $268,000 by the University of Pennsylvania (NIH-National Institute on Aging) for the project titled, A Training and Fidelity Model to Move and Scale Evidence-based Dementia Care and Caregiver Support Programs into Practice: The Case for COPE in PACE Service Setting.

GirijaKaimal,EdD, assistant professor in the Creative Arts Therapies Department in the College of Nursing and Health Professions, was awarded $300,00 by the National Endowment for the Arts for the project titled, Cortical hemodynamic response among infants of mothers with and without PPD.

MinjungShim, PhD,assistant research professor in the Creative Arts Therapies Department in the College of Nursing and Health Professions, was awarded $234,000 by Health and Human Services-NIH for the project titled, Mindfulness-Based Dance/Movement Therapy for Chronic Low Back Pain.

The Urban Health Collaborative (UHC) and Ana Diez Roux, MD, PhD, dean and UHC director in the Dornsife School of Public Health, will lead a $385,000 pilot study aimed at improving cancer-related health outcomes in Philadelphia neighborhoods. The project, called Community IMPACT, is a partnership with Dana Dornsife and the Lazarex Cancer Foundation. UHC, with the College of Nursing and Health Professions and the College of Medicine, will combine public health qualitative and quantitative assessment and research methods with grassroots community engagement through funding by the Silicon Valley Community Foundation.

An interdisciplinary team led by Fraser Fleming, PhD, professor of chemistry in the College of Arts and Sciences, received a $500,000 grant from the National Science Foundation for their project Creative Interdisciplinary Research in Graduate Education. The team includes Paul Gondek, PhD, visiting research professor of chemistry in the College of Arts and Sciences; Daniel King, PhD, associate professor of chemistry in the College of Arts and Sciences; Jen Katz-Buonincontro, PhD, associate professor and associate dean of research in the School of Education; and D.S. Nicholas, assistant professor in the Westphal College of Media Arts & Design. They will use the grant to develop and implement a Drexel graduate minor in creative, interdisciplinary research.

Brian Daly,PhD, interim department head and associate professor of psychology in theCollege of Arts and Sciences,was awarded a three-year $150,000grant from the Pew Charitable Trusts to deliver and evaluate a socioemotional learning program for elementary school children attending Philadelphia public schools.

Gwen Ottinger, PhD, associate professor of politics in the College of Arts and Sciences, received $100,000 from theValero/Benicia Good Neighbor Steering Committeefor her project Air Watch Bay Area, which makes real-timeair quality monitoringinformationand reportingmore accessible to residents.

Andrew Cohen, PhD, associate professor in the Department of Electrical and Computer Engineering in the College of Engineering,serves as principal investigator (PI) on a grant titled, A spatiotemporal map of signaling processes controlling human stem cell renewal and differentiation, which has been funded by the Human Frontiers Science Program. The funding is $350,000 per year for three years.

The LeBow College of Business Stacy Kline,clinicalprofessor of accounting, and Barbara Grein, PhD, associate professor and department head of accounting,received a PwCINQuiriesGrant for $10,000 to support curriculum development inthe LeBow College of BusinessAccountingDepartment.

Go here to read the rest:
Faculty Highlights: Recent Grants and Awards | Now - Drexel Now

The Aesthetic Medicine Congress to bring trends in plastic surgery to Dubrovnik – The Dubrovnik Times

"The Aesthetic Medicine Congress", in collaboration with the British College of Aesthetic Medicine, takes place at the Hotel Palace from October 11 to 13. Top international and local experts will present trends in aesthetic medicine, rejuvenation and facial and body shaping for around 400 announced participants.

In addition to presenting the latest technology and research results, there will also be live demonstrations, interactive panels and lectures on topics ranging from aesthetic medicine to medical tourism.

The Second Congress of Aesthetic Medicine in Dubrovnik, under the high auspices of the President of the Republic of Croatia, Kolinda Grabar-Kitarovic, will be opened by Tourism Minister Gari Cappelli.

Apart from Croatia and the region, participants from Congress come from Britain, Ireland, Italy, Germany, Netherlands, Belgium, Switzerland, France, Greece, USA, Mexico, India, UAE

The famous names of aesthetic medicine are coming to the congrees, such as Raj Kanodia, Tapan Patel, Matt Stefanelli, Bob Khanna, Herve Raspaldo, Tracy Mountford, Tom van Eijk, Iman Nurlin, Dimitris Sykianakis, Ravi Jain and David Ecclestone. The local experts and lecturers are Sinisa Glumicic, Mario Zambelli, Nikola Milojevic, Davor Mijatovic, Zoran Zgaljardic, Tomica Bagatin, Zeljana Bolanca, Aleksandar Milenovic, Mladen Dudukovic and others.

TAMC 2019 is an international aesthetic congress that offers an interactive, evidence-based, multidisciplinary program and provides a platform to encourage the exchange of ideas and experiences, educate, initiate intense discussions, and expand opportunities for new contacts.

TAMC 2019 covers all aspects of aesthetic medicine, and this year's highlights include: anti-aging and face shaping dermal fillers, skin rejuvenation treatments including stem cell and blood plasma treatments, aesthetic gynecology, life extension (gerontology), body shaping and fat reduction, Botulinum toxin type A basic and advanced techniques, complication management, anatomy, cosmetic surgery, cosmetic dentistry, patient communication, business building and marketing, as well as medical tourism.

Read the original post:
The Aesthetic Medicine Congress to bring trends in plastic surgery to Dubrovnik - The Dubrovnik Times

Stem Cells Market : Insights Into the Competitive Scenario of the Market – Online News Guru

In theglobal stem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=132

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

Read this article:
Stem Cells Market : Insights Into the Competitive Scenario of the Market - Online News Guru

‘Rewind Therapeutics’ and Remyelination – SciTech Europa

At Rewind Therapeutics (a start-up company based in Leuven, Belgium), we focus on the development of treatments for neurological diseases. Myelin is the insulation that wraps around neurons, and in turn, helps neurons to work faster and more efficiently. It is also the target of autoimmune attacks in multiple sclerosis (MS), and any damage to myelin is the proximate cause of the symptoms of the disease.

Myelin is formed by glial cells in the brain called oligodendrocytes; oligodendrocytes and their precursors account for about 30% of all the cells in the brain. The brain has a significant capacity to repair myelin when it is damaged. Repair is accomplished by mobilising stem cells called oligodendrocyte precursor cells (OPCs), which can migrate to the location of the myelin damage and differentiate into oligodendrocytes.

Failure of repair is associated with disability in diseases such as MS. The progression of disability in MS (a separate process from the relapses and remission that are the hallmark of the early stages of the disease) is believed to be associated with the brains failure to repair myelin. Myelin repair is a tightly regulated process, with mechanisms that both promote and inhibit repair. By manipulating the inhibitory processes, we hope to remove the brakes so the repair process works more efficiently.

Historically, treatments for neurological diseases have focused on neurons. While neurons are undoubtedly important, they represent perhaps less than half the cells in the brain. What is emerging is the appreciation that cells in the brain other than neurons can be the target for drugs that treat brain disease.

These other cell types include oligodendrocytes (which is what we focus on), but also astrocytes and microglia. New companies are emerging that are focused on developing therapeutics that target these other cells. This includes companies that are developing small molecule therapeutics, a few companies that are making biologics (antibodies) as well as a couple of companies that are focused on cell-based therapies.

MS is the immediate focus of our therapeutic efforts. We know that the disease results from autoimmune attacks on myelin, and these periodic attacks cause the initial symptoms of the disease. Over time, MS is associated with a progressive disability, so that patients are ultimately confined to a wheelchair and have several other disabilities. It is believed that this progressive disability reflects the loss of myelin, and the loss of the normal capacity to repair myelin enhancing that capacity is our goal.

Oligodendrocyte development from OPCs has been studied for many years. We know a lot of the details in cellular and molecular terms, but there are still many unknowns. However, we do have the ability to study oligodendrocytes and their interactions with neurons in experimental models. Some of these models come from rodents, and it is also possible to make oligodendrocytes (and neurons) from human induced pluripotent stem cells (we use both). The use of these models has enabled the field to identify new drug targets, and to test new therapeutics.

The availability of these models enabled compound screening, and several studies published in the last three to four years reported successful repurposing screens where existing drugs were shown to promote remyelination both in vitro and in vivo. Based on these studies, at least one compound (clemastine) was taken into a clinical trial, and the trial demonstrated a successful proof of mechanism. This was the demonstration of a repair effect on the optic nerve, using visual evoked potentials, which suggests that the compound promoted remyelination. So far, no one had demonstrated an effect on a therapeutic endpoint using a remyelination approach.

Although a lot of preclinical work has suggested that manipulation of remyelination targets can improve myelination in animal models, we do not yet know how these effects will translate into clinical effects. We are still trying to learn how to translate observations in animal models into an impact on clinical disease.

The therapeutic goal in MS is to slow progression of the disability associated with the disease. Historically, it has been difficult to develop drugs that slow the progression of neurodegenerative diseases. Indeed, the success in doing this in the pharma industry is essentially zero. This is a challenging goal. However, promoting remyelination is a novel approach to treating neurodegeneration.

Myelin damage is associated with several neurological disease other than MS. There are other autoimmune diseases, such as neuromyelitis optica spectrum disorder, that are conceptually similar to MS but which lack approved therapies. Multiple system atrophy is a progressive neurodegenerative disease where the pathology may originate from alpha synuclein deposits in oligodendrocytes (unlike Parkinsons disease, where the alpha synuclein deposits are in neurons).

In addition to this, there are several leukodystrophies that are characterised by myelin damage. In acute brain injuries (such as stroke and traumatic brain injury), there is clearly damage to myelin. In these other disease areas, it is not yet clear whether remyelination therapies will have a therapeutic effect, but there are many exciting therapeutic areas to explore.

Dr Ian J. Reynolds

CEO

Rewind Therapeutics

+32 (0) 470858910

ian.reynolds@rewindtherapeutics.com

Read more:
'Rewind Therapeutics' and Remyelination - SciTech Europa

Greenwood to step down as CEO of BIO after 2020 election – FierceBiotech

Jim Greenwood is set to step down as CEO of the Biotechnology Innovation Organization (BIO) after the 2020 election. Greenwood has held the position for more than half of BIOs history but will now make way for a new leader who will work to defend innovation from domestic political attacks.

Under Greenwoods leadership, BIO tripled in size, growing from a relatively small player in 2005 to a 176-employee organization with an $85 million operating budget. BIO has almost doubled its annual outlay on lobbying under Greenwood, going from spending a little more than $5 million in 2004 to just shy of $10 million last year, according to data tracked by the Center for Responsive Politics.

The increase in spending has covered a period in which BIO has fought to protect drug developers from the perceived threats of government actions. Those threats are arguably as acute today as at any point during Greenwoods reign, and the CEO plans to go out fighting.

CIOs Perspectives: Driving Clinical Trial Innovation with a Unified Platform

IT is being challenged with either trying to fix and maintain an already complex system of solution integrations, or exploring driving business impact by unifying its systems under one platform. Attend and learn about the IT benefits to shifting resources away from disparate systems and moving towards a unified platform.

I will continue my full-throated advocacy to ensure our elected officials do not kill innovation in a populist furor and prevent our scientists from delivering a new generation of genomic cures, Greenwood said in a statement.

The timing of Greenwoods departure means he will continue to make the case for biotech until the end of this election cycle and help support the transition to a new BIO leader in 2021.

Greenwood took over as leader of BIO from its founding president Carl Feldbaum in 2005. Before joining BIO, Greenwood spent 12 years as a Republican member of the House of Representatives. BIO lists efforts to modernize the FDA and lift a ban on embryonic stem cells among the initiatives Greenwood worked on during his time in Congress.

Since leaving to join BIO, Greenwood has continued to shape legislation, leading the industry side of negotiations about the Prescription Drug User Fee Act and the 21st Century Cures Act. Those negotiations have affected how drugs are developed for the U.S. market.

See more here:
Greenwood to step down as CEO of BIO after 2020 election - FierceBiotech

Catholics more motivated to donate if ethical investing is assured – Crux: Covering all things Catholic

WASHINGTON, D.C. Nearly nine in 10 Catholics surveyed said they want their donations to church institutions to be ethically invested and a majority of those responding voiced particular opposition to investments in companies that produce pornography, tobacco products and e-cigarettes, according to a new survey.

The survey for Boston-based Catholic Investment Services found that about 87 percent of respondents would be more likely to donate to Catholic institutions if they knew the money would be invested in ways consistent with church teaching and values.

In contrast, about 14 percent of respondents said ethical investing was not a consideration when donating to Catholic institutions.

The results parallel those of a CIS survey released in April. Peter Jeton, the firms outgoing CEO, said the new study sought to more specifically identify what investments motivate or deter Catholics to give to church entities.

People want their donations to go where its good and avoid evil, Jeton said.

Ethical investing can be a motivating factor in how much people give, he told Catholic News Service. And if I am the CFO (chief financial officer) of a diocese or if Im the bishop of a diocese, then I should be explaining very clearly and with frequency what the policy is regarding how peoples money is being invested.

The survey involved 500 Catholic adults who answered a series of online questions Sept. 7-9. It has a margin of error of plus or minus 4.5 percentage points.

It covered more than a dozen types of businesses from manufacturers of medications used during an abortion procedure to oil and natural gas mining to which respondents voiced objections.

In the case of the pornography industry, 60% of respondents said church money should not be invested in such endeavors. Opposition also was raised to investing in tobacco products and e-cigarettes (57 percent), alcoholic beverages (52 percent), medications used during an abortion (52 percent), casinos and gaming (51 percent), medical facilities where abortions occur (50 percent), gun manufacturing (47 percent), for-profit prisons/detention centers (45 percent), security, defense and large-scale weapons (44 percent), research on embryonic stem cells (37 percent), manufacturers of birth control (31 percent) and oil and natural gas extraction (30 percent).

Jeton suggested that institutional financial officers and bishops be fully transparent about their investment decisions. The better the engagement, the better for the Church, he said.

They should emphasize the link with Catholic social teaching, he added. Because if our data is correct, then making people in the pews aware of that should, by all rights, increase the comfort level with the Church and a greater willingness to share more of their financial resources with the Church.

The survey also asked participants what investments Catholic institutions should be making. Among those cited by respondents were clean air and water (67 percent), workforce education/job training (66 percent), education technology (65 percent), agriculture and food (65 percent), health care providers (62 percent), affordable housing (60 percent), recycling (57 percent), renewable energy (53 percent), land conservation (50 percent), fitness/nutrition (49 percent) and banking and financial services to low-income people and small businesses (46 percent).

Catholic Investment Services was founded in 2013 to serve Catholic entities, including dioceses, colleges and universities, hospital systems and social service agencies. Jeton said the firm follows the socially responsible investment guidelines adopted by the U.S. Conference of Catholic Bishops.

Those guidelines, in place since 2003, are divided into six broad categories: protecting human life, promoting human dignity, reducing arms production, pursuing economic justice, protecting the environment and encouraging corporate responsibility. Each category lists specific areas of concern, such as abortion, racial discrimination, labor standards and other social needs in which the Church has had a voice.

Jeton said he hoped the data developed would influence how diocesan bishops in particular discuss finances with the folks in the pew.

They would do well to pay attention to mechanisms that would get more people engaged, Jeton said. Hopefully with greater engagement there is growing willingness (among donors) to go into their back pocket to help the Church.

Crux is dedicated to smart, wired and independent reporting on the Vatican and worldwide Catholic Church. That kind of reporting doesnt come cheap, and we need your support. You can help Crux by giving a small amount monthly, or with a onetime gift. Please remember, Crux is a for-profit organization, so contributions are not tax-deductible.

The rest is here:
Catholics more motivated to donate if ethical investing is assured - Crux: Covering all things Catholic

Epigenetic initiation of the TH17 differentiation program is promoted by Cxxc finger protein 1 – Science Advances

INTRODUCTION

T helper 17 (TH17) cells, a subset of CD4+ T cells, are characterized by the secretion of interleukin-17A (IL-17A), IL-17F, IL-21, IL-22, and the transcription factors (TFs) retinoic acid receptorrelated orphan receptor t (RORt) and ROR (13). RORt and ROR are critical drivers of autoimmune tissue inflammation in human autoimmune diseases (multiple sclerosis), mouse models [experimental autoimmune encephalomyelitis (EAE)], and other autoimmune conditions (4). TH17 cells also maintain mucosal tissue homeostasis and contribute to the host defense against bacterial and fungal infections (2, 5). The activation of naive TH cells in the presence of transforming growth factor1 (TGF-1) and IL-6 leads to the development of TH17 cells (6). Other cytokines such as IL-21, IL-1, and IL-23 are crucial for the expansion, stability, and functional maturation of TH17 cells (4, 6, 7). RORt and ROR are the master regulators of TH17 cells, and other TFs, c-Maf, IRF4 (interferon regulatory factor 4), BATF (basic leucine zipper transcription factor, ATF like), and IkB, are required for the induction of RORt, IL-17, IL-21, and IL-22 in vivo and in vitro (8). IL-6, IL-21, and IL-23 can all activate signal transducers and activators of transcription 3 (STAT3), and the activation of STAT3 is crucial for their effects on TH17 cell differentiation (1). The impairment of STAT3 skews TH17 differentiation toward anti-inflammatory Treg cells, and TAZ [transcriptional coactivator with postsynaptic density 65discs largezonula occludens 1binding (PDZ) motif]/TEAD1 (TEA-ATTS DNAbinding domain 1) regulates reciprocal RORt/Foxp3 expression downstream of STAT3 (9).

Epigenetic mechanisms such as DNA methylation and histone acetylation/methylation have been reported as key players in different T cell subsets (10). In TH1 cells, permissive histone modifications and DNA demethylation in interferon- (IFN-) and Tbx21 could promote IFN- expression and help TH1 lineage differentiation and stability (10, 11). The TH2-specific genes (IL4, IL5, and IL13) are repressed by suppressive histone modifications and DNA methylation in the process of TH1 cell differentiation (12). However, TH2 cells contain activated histone modifications and undergo DNA demethylation at the TH2-specific gene cluster, as well as contain repressive histone modifications and undergo DNA methylation in TH1-specific genes (IFN- and Tbx21) (13). Foxp3, the master TF for Treg cells, was marked with permissive H3K4me3 modification and underwent DNA demethylation at its gene locus, which contributes to the determination and commitment of the Treg cell lineage (14). Similarly, genome-wide epigenetic analysis of TH17 cells uncovered the enrichment of permissive histone modifications such as H3K4me3 and DNA demethylation in the promoters of cytokine and lineage-specific genes such as IL17a, IL17f, IL21, IL23r, and Rorc (15).

CXXC finger protein 1 (Cxxc1), defined as an epigenetic regulator, binds to DNA using its CXXC finger domain and recruits SETD1 to most CpG islands (CGIs) through its Setd1-interacting domain (16, 17). Clouaire et al. (16) showed that Cxxc1 is required for H3K4me3 modification in embryonic stem cell, and Thomson et al. (18) found a concordance of Cxxc1 binding with H3K4me3 and nonmethylated CGIs in mouse brain. Our recent studies also demonstrated that Cxxc1-dependent H3K4me3 plays a critical role in thymocyte development, phagocytosis, and the bactericidal activity of macrophages (19, 20). However, the role of Cxxc1-mediated H3K4 trimethylation and DNA methylation in TH cells remains unclear.

To explore the role of Cxxc1 in TH cell differentiation, we took advantage of T cellspecific Cxxc1 knockout (KO) mice. Here, we demonstrate that Cxxc1-deficient TH17 cells exhibited impaired differentiation and stability, which led to susceptibility to bacterial infection and protected against EAE in vivo. Fluorescence-activated cell sorting (FACS) and RNA sequencing (RNA-seq) analyses identified that Cxxc1 deficiency skews TH17 differentiation toward anti-inflammatory Treg cells both in vivo and in vitro.

Via chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-seq) analysis, we revealed genome-wide Cxxc1-binding sites in TH17 cells and H3K4me3 modification changes in Cxxc1-deficient TH17 cells compared with the wild-type (WT) control. We found that Cxxc1 bound to IL-6R and other TFs (IRF4 and BATF) by maintaining the appropriate H3K4me3 modification of their promoter regions. Moreover, IL-6R, a direct target of Cxxc1, could partially rescue the differentiation and stability defects seen in Cxxc1-deficient TH17 cells. Cxxc1 thus reciprocally regulates the balance between TH17 and Treg cells by regulating IL-6/STAT3 signaling. This suggests that the Cxxc1-mediated epigenetic program is required for T cell differentiation and TH17-related autoimmune diseases.

To investigate the potential role of Cxxc1 in TH cell function, we generated conditional KO mice by crossing mice with loxP-flanked Cxxc1 alleles to mice with transgenic Cre driven by the distal Lck promoter (dLck-Cre mice), which mediated the deletion of genes on peripheral CD4+ and CD8+ T cells. dLckcreCxxc1fl/fl mice developed normally with no obvious difference in their T cell development in the thymus (fig. S1A). Further analysis of the peripheral T cells showed a decrease in CD8+ T cell numbers, especially in its effector/memory population, while CD4+ T cell numbers and phenotypes were normal (fig. S1, B to D). CellTrace dilution showed little impairment of the CD8+ T cell proliferation capacity of Cxxc1-deficient T cells cultured under T cell receptor (TCR) stimulation, while CD4+ T cells showed no influence of TCR stimulation (fig. S1E).

We then isolated naive CD4+ T cells from dLckcreCxxc1wt/wt and dLckcreCxxc1fl/fl mice and conducted T cell differentiation in vitro. We found that Cxxc1 ablation led to severely defective TH17 differentiation characterized by reduced IL-17A and IL-17F in two TH17 cellpolarizing conditions: (i) TGF-1 and IL-6 and (ii) IL-1, IL-6, and IL-23, while Foxp3 expression increased (Fig. 1, A and B). However, Cxxc1-deficient T cells exhibited no obvious difference in TH1 or TH2 differentiation and a moderate increase in induced T-regulatory cell (iTreg) differentiation (fig. S2, A to C), while the expression levels of Cxxc1 protein were consistent among these T helper subsets and in different stimulation time of TH17 cells (fig. S2, G and H). Furthermore, we also used CD4+ T cells from CreERT2+ Cxxc1fl/fl mice to test Cxxc1 function in an in vitro culture system and found a similar requirement for Cxxc1 in TH17 differentiation in the presence or absence of 4-hydroxytamoxifen treatment (which initiated the access of Cre recombinase to the nucleus and led to the deletion of Cxxc1 in vitro, as shown in fig. S2I) (Fig. 1, C and D) for 4 days, and we observed no obvious difference in TH1, TH2, or iTreg differentiation (fig. S2, D to F).

(A and B) Naive CD4+ T cells (CD4+CD25-CD62LhiCD44lo) from dLckcreCxxc1fl/fl or WT mice were differentiated into TH17 cells with (A) IL-6 and TGF-1 or (B) IL-1, IL-6, and IL-23 for 96 hours and then restimulated for intracellular cytokine staining. One of five to seven experiments is shown. (C and D) Naive CD4+ T cells (CD4+CD25-CD62LhiCD44lo) from ERT2creCxxc1fl/fl mice were differentiated into TH17 cells with (C) IL-6 and TGF-1 or (D) IL-1, IL-6, and IL-23 for 96 hours in the presence or absence of 4-OHT (4-Hydroxytamoxifen) and then restimulated for intracellular cytokine staining. One of five experiments is shown. (E and F) Naive CD4+ T cells from RORtcreCxxc1fl/fl or WT mice were differentiated into TH17 cells with (E) IL-6 and TGF-1 or (F) IL-1, IL-6, and IL-23 for 96 hours and then restimulated for intracellular cytokine staining. One of seven experiments is shown. (G) Intracellular staining of IL-17A in lipoprotein lipase (LPL) CD4+ T cells in the small intestines of RORtcreCxxc1fl/fl and WT mice. One of four experiments is shown. Error bars show the means SD. **P 0.01, ***P 0.001, ****P 0.0001 using the Students t test.

Next, we tested the function of Cxxc1 in TH17 cells by generating RORtcre Cxxc1fl/fl mice. Similar to the dLck-mediated deletion of Cxxc1, RORtcre Cxxc1fl/fl mice developed normally in terms of T cell development in the thymus (fig. S3A) and exhibited decreased CD8+ T cell numbers in the periphery (fig. S3, B and D), while CD4+ T cell numbers were normal (fig. S3, B and C). Then, we isolated naive CD4+ T cells from RORtcreCxxc1wt/wt and RORtcre Cxxc1fl/fl mice and conducted TH17 cell differentiation (TGF-1 and IL-6 or IL-1, IL-6, and IL-23) in vitro. Compared with the dLck-mediated deletion of Cxxc1, T cells in RORtcreCxxc1fl/fl mice differentiated under TH17 cellpolarizing conditions showed much less IL-17A and IL-17F production than Cxxc1-competent RORtcreCxxc1wt/wt cells and markedly increased Foxp3 production (Fig. 1, E and F). This is due to the sufficient deletion of Cxxc1 protein in TH17 cells in the RORtcre system compared with dLckcre system (fig. S2I). Under steady-state conditions, TH17 cells are preferentially located in the lamina propria (LP) of the small intestine (3). We also showed that CD4+ T cells in the LP of RORtcre Cxxc1fl/fl mice showed notably reduced IL-17 production in vivo (Fig. 1G), although we found a little increased frequency of Treg cells in LP and normal frequency of Treg cells in lymph nodes and spleen (fig. S3E).

To characterize IL-17A expression more specifically, we introduced IL-17AeGFP reporter mice into dLckcreCxxc1fl/fl and RORtcre Cxxc1fl/fl backgrounds separately, and the results also confirm defective TH17 differentiation in Cxxc1-deficient cells with enhanced green fluorescent protein expression (fig. S3, F and G). These results indicate that Cxxc1 is essential for TH17 cell differentiation in vitro.

To further evaluate whether defects in TH17 cells caused by Cxxc1 deficiency affect the development of TH17-dependent inflammatory diseases in vivo, we used a TH17-dependent autoimmune disease model, EAE, that mimics the human neuroinflammatory disease multiple sclerosis.

As we found decreased CD8+ T cell numbers in the periphery (fig. S3B), to exclude the effect of CD8+ T cell (21), we sorted naive CD4+ T cells (CD4+CD44loCD62L+) from RORtcreCxxc1fl/fl and RORtcreCxxc1wt/wt mice, transferred these cells into Rag1/ mice, and then monitored them for the induction of EAE. In agreement with the results showing the in vitro defects, transfer of RORtcreCxxc1fl/fl-naive CD4+T cells alleviated EAE, and significantly less mononuclear cell infiltration and demyelination of the spinal cord were observed (Fig. 2, A and B). Within the central nervous system (CNS)infiltrating draining lymph nodes and spleen CD4+ T cell population, the production of IL-17A+ T helper cells was reduced in the hosts that had received RORtcreCxxc1fl/fl cells, whereas the number of Treg cells increased in the CNS-infiltrating CD4+ T cells (Fig. 2, C and D). Cxxc1-deficient splenocytes isolated from myelin oligodendrocyte glycoprotein (MOG)immunized mice showed impaired production of IL-17 but normal production of IFN- upon restimulation with the MOG peptide compared with Cxxc1-sufficient splenocytes (Fig. 2E). We found similar results when the EAE model was induced in the Rag1/ hosts with dLckcreCxxc1fl/fl cells compared with dLckcreCxxc1wt/wt cells (fig. S4, A to C). We can find that Cxxc1 deficiency alleviated symptoms of autoimmunity in dLckcreCxxc1fl/fl (fig. S4, D to G) and RORtcreCxxc1fl/fl (fig. S4, H to K) mice compared with appropriate control mice as well. These data suggested that the Cxxc1-deficient cells were less susceptible to the EAE disease model than Cxxc1-sufficient cells, which was in accordance with the in vitro results showing defective IL-17 expression.

(A) Mean clinical scores for EAE in Rag1/ recipients of RORtcreCxxc1fl/fl (n = 13) or WT (n = 11) naive CD4+ T cells after being immunized with MOG3555, complete Freunds adjuvant (CFA), and pertussis toxin. Data are summed from three independent experiments. (B) Representative histology of the spinal cord of Rag1/ mice after EAE induction (day 25). Hematoxylin and eosin (H&E) staining (left), Luxol fast blue (F&B) staining (right). (C) On day 20 after the induction of EAE in Rag1/ hosts, CD4+ T cells were analyzed from leukocytes isolated from the CNS, draining lymph nodes (dLNs), and spleen and further analyzed for the frequency of IL-17A+ and IFN-+ T cells (left). Summary of CNS IL-17A+CD4+ and IFN-+CD4+ T cells in Rag1/ hosts (right). One representative of three experiments is depicted. (D) The frequency of Foxp3+ cells from CNS-infiltrating lymphocytes in Rag1/ EAE mice was determined at day 20 after immunization (top). Summary of CNS Foxp3+CD4+ cells in Rag1/ hosts (bottom). One representative of three experiments is depicted. (E) Splenocytes were rechallenged with the MOG peptide (0, 5, and 25 g/ml) for 3 days, and then, cytokine production was measured by enzyme-linked immunosorbent assay (ELISA). (F) Body weight changes of Rag1/ recipients of naive CD4+ T cells from RORtcreCxxc1fl/fl (n = 12) or WT (n = 11) mice after oral inoculation with C. rodentium at the indicated time points. Data are summed from three independent experiments. (G) Colon length for Rag1/ recipients of naive CD4+ T cells from RORtcreCxxc1fl/fl or WT mice after oral inoculation with C. rodentium at day 7. Summary of colon lengths in Rag1/ hosts (right). (H) Histological analysis of representative colons from Rag1/ hosts 7 days after inoculation. (Photo credit: Feng Lin, Institute of Immunology, Zhejiang University School of Medicine). (I) C. rodentium colony-forming units (CFUs) in the colon 7 days after inoculation. Data are summed from three independent experiments. (J) FACS analysis of IL-22 expression from isolated LPLs in Rag1/ hosts at day 7 after inoculation. One of five experiments is shown. Error bars show the means SD. *P 0.05, **P 0.01, ***P 0.001 using the Students t test.

IL-22 is produced by leukocytes, particularly TH17 cells, and has a crucial role in host defense against bacterial infections. Ouyang and his team (5) found that IL-22 has a crucial role in the early phase of host defense against Citrobacter rodentium. We sorted naive CD4+ T cells from RORtcreCxxc1fl/fl and RORtcreCxxc1wt/wt mice, transferred these cells into Rag1/ mice, and then inoculated them with C. rodentium. On day 7 after inoculation, mice that had undergone transfer of RORtcreCxxc1fl/fl-naive CD4+ T cells developed a more aggravated infection than mice that had undergone transfer of RORtcreCxxc1wt/wt-naive CD4+ T cells. The mice showed a significantly greater loss of body weight and shorter colon length than the WT mice (Fig. 2, F and G). Histological analysis of colons from C. rodentiuminfected RORtcreCxxc1fl/fl mice showed increased mucosal hyperplasia and submucosal inflammation compared to the RORtcreCxxc1wt/wt mice, suggesting that Cxxc1 deficiency leads to compromised epithelial barrier function (Fig. 2H). In addition, we found that the bacterial burdens in the feces of RORtcreCxxc1fl/fl mice were increased compared to those in the feces of RORtcreCxxc1wt/wt mice (Fig. 2I). Cytokine analysis showed reduced IL-22 production in CD4+ T cells and group 3 innate lymphoid cell (ILC3) from the LP of hosts with Cxxc1-deficient cells transfer (Fig. 2J and fig. S5A), and ILC3s IL-22 production impairment is possibly due to increased Treg cells (fig. S5B) (22). We found that IL-17 production was unaffected, which imply that cytokines other than IL-6 may regulate IL-17 in this model, and we found normal STAT3 phosphorylation by IL-21 stimulation of RORtcreCxxc1fl/fl cells (fig. S5, C and D). In addition, we found similar results when we performed C. rodentium model in RORtcreCxxc1fl/fl mice (fig. S5, E to H). These findings further support the conclusion that Cxxc1 contributes to TH17 differentiation and function in vivo.

To further analyze the genes regulated by Cxxc1, we performed RNA-seq analysis of RORtcreCxxc1fl/fl and RORtcreCxxc1wt/wt TH17 cells generated in vitro in the presence of TGF- and IL-6 for 72 hours. The RNA-seq results showed that Cxxc1-deficient TH17 cells almost completely lost their features and exhibited a Treg celllike expression profile. Key TH17 cellrelated cytokines and transcripts (e.g., Il17a, Il17f, Il21, Il22, Il6ra, Irf4, Cxcr4, Maf, and Satb1) were significantly down-regulated in RORtcreCxxc1fl/fl TH17 cells, and the master TFs Rorc and Rora also showed a decrease in expression (Fig. 3, A and B). Key Treg cellrelated transcripts (e.g., Foxp3, Ccl3, Itgae, Gpr83, Mgat5, Ikzf2, Ikzf4, Tigit, and Tnfsf10) were significantly up-regulated in RORtcreCxxc1fl/fl TH17 cells (Fig. 3, A and B). Using a fold change of 2 and P < 0.05 to threshold parameters, we found that 782 genes were down-regulated by Cxxc1 knockdown in Cxxc1-defcient cells, and 1411 genes were up-regulated. By pathway analysis, we found the significant enrichment of many genes associated with the inflammatory response and immune-related signaling pathways (e.g., the Janus kinaseSTAT cascade and tyrosine phosphorylation of STAT3 protein) (Fig. 3C). We then measured the expression of TH17 and Treg signature genes, including Il17a, Il17f, Il21, Il22, Rorc, Il6ra, Foxp3, Mgat5, Itgae, Gpr83, Tgfbr1, and Ccl3, from Cxxc1-deficient cells and Cxxc1-sufficient cells by quantitative polymerase chain reaction (qPCR) and obtained the same results as those from 72-hour RNA-seq analysis (Fig. 3D). We also verified these genes in dLCK-Creinduced Cxxc1-deficient TH17 cells by qPCR and got the same results (fig. S5I), which indicates that Cxxc1-deficient TH17 cells exhibit a Treg celllike expression profile.

(A) Naive CD4+ T cells (CD4+CD25CD62LhiCD44lo) from WT and RORtcreCxxc1fl/fl mice were differentiated in the presence of TGF-1 and IL-6 (TH17) for 72 hours, and the total RNA from the cells was analyzed by RNA-seq [STAR (structured transparent accessible reporting) method]. Scatter diagram showing changes in gene expression in WT and Cxxc1-deficient TH17 cells. Down-regulated genes are indicated in blue; up-regulated genes are indicated in red. (B) Heatmap of the fold change (log2) for differentially expressed genes (false discovery rate < 0.05 in TH17 cells is shown). (C) Pathway analysis of the down-regulated genes (left) and up-regulated genes (right). (D) The expression of the selected transcripts was quantified in TH17 cell samples differentiated from naive CD4+ T cells with TGF-1 and IL-6 for 72 hours by real-time qPCR. One of five experiments is shown. Error bars show the means SD. *P 0.05, **P 0.01, ***P 0.001 using the Students t test.

Cxxc1 has two main functional domains. One domain is the N-terminal domain, which interacts with unmethylated CpG DNA to mediate its interaction with DNA methyltransferases 1 (DNMT1) and stabilizes the DNMT1 protein to regulate DNA methylation (17, 18, 23). The other is the C-terminal domain, which interacts with the Setd1 H3K4 methyltransferase complex through the Smad interaction domain to regulate histone methylation. An N-terminal fragment of Cxxc1 (residues 1 to 367) and Cxxc1 containing the point mutation C375A retain their interaction with DNMT1, but the Setd1-interacting activity of Cxxc1 is interrupted. While the C-terminal fragment of Cxxc1 (residues 361 to 656) and Cxxc1 containing the point mutation C169A still have Setd1-interacting activity and can methylate H3K4, the DNA binding activity of Cxxc1 is interrupted. To explore which functional domains within Cxxc1 were necessary for its role in TH17 differentiation, we used an in vitro TH17 differentiation system, and different vectors expressing mutated Cxxc1 proteins were overexpressed in Cxxc1-deficient TH17 cells. The overexpression of full-length Cxxc1 notably rescued the TH17 differentiation defects seen in Cxxc1-deficient cells (fig. S6A). The overexpression of the two Cxxc1 fragments (residues 1 to 367 and residues 361 to 656) and Cxxc1 containing two point mutations (C169A and C375A) showed that the C-terminal domain of Cxxc1 (residues 361 to 656, C169A) rather than the N-terminal domain of Cxxc1 (residues 1 to 367, C375A) was able to rescue TH17 differentiation in Cxxc1-deficient TH17 cells (fig. S6, A and B). Similarly, the overexpression of the C-terminal domain of Cxxc1 reduced Foxp3 expression in Cxxc1-deficient TH17 cells, but the overexpression of the N-terminal domain of Cxxc1 did not (fig. S6C). We also checked gene expression changes by real-time PCR, such as TH17 and Treg signature genes, including Il17a, Il17f, Il21, Il22, Rorc, Il6ra, Foxp3, Mgat5, Itgae, Gpr83, Tgfbr1, and Ccl3, further elucidating the role of two CXXC1 functional domains (fig. S6D). These data showed that the Setd1-interacting domain but not the DNA binding domain in Cxxc1 is crucial for TH17 differentiation, indicating that Cxxc1 may function through regulating H3K4me3 rather than through DNA methylation in TH17 cells.

To investigate the direct targets of Cxxc1 in TH17 cells, we performed ChIP-seq to map genome-wide Cxxc1-binding sites in WT TH17 cells, as well as in Cxxc1-deficient TH17 cells serving as a negative control. Compared with Cxxc1-binding sites in the mouse genome, an obvious enrichment of Cxxc1-binding sites was found in gene promoters [5-kb upstream and downstream of the transcription start site (TSS), 25.56% of Cxxc1-binding sites versus 2% of the mouse genome], exons (3.52% versus 2%), introns (32.67% verus 20%), and intergenic regions (38.25% versus 76%) (Fig. 4A). This represented a relatively high degree of enrichment at promoter regions compared with the distribution of Cxxc1-binding sites in the mouse genome. Analysis of the average binding location also showed that Cxxc1 showed high binding activity at TSS (Fig. 4B).

(A) Naive CD4+ T cells (CD4+CD25-CD62LhiCD44lo) from WT and RORtcreCxxc1fl/fl mice were differentiated in the presence of TGF-1 and IL-6 (TH17) for 24 hours, and ChIP-seq analysis was conducted to map genome-wide Cxxc1-binding sites in WT TH17 cells. Distribution of the genetic features across the whole mouse genome (mm10) (left) and the distribution of Cxxc1-binding peaks in TH17 cells (right). (B) Distribution of Cxxc1-binding peaks across extended gene bodies in TH17 cells. The tag density of Cxxc1 binding to gene bodies [between the transcription start site (TSS) and the transcription termination site (TTS)], as well as 3-kb upstream of the TSS and 3-kb downstream of the TTS regions of all RefSeq (mm10) genes, was calculated. (C) Enrichment of Cxxc1-binding peaks on CGIs. The tag density of Cxxc1 binding to CGIs and 5-kb flanking regions was calculated. (D) Overlapped regions between Cxxc1-binding sites, H3K4me3 sites, and RNA-seq down-regulated genes in WT and Cxxc1-deficient TH17 cells. (E) Integrative Genomics Viewer browser view of Cxxc1-binding peaks (red) in WT TH17 cells and H3K4me3 markers (blue) in WT and Cxxc1-deficient TH17 cells. (F) Naive WT CD4+ T cells were sorted and cultured under TH17 differentiation conditions (TGF- and IL-6) for 24 hours, and ChIP-qPCR analysis of Cxxc1 binding at the indicated gene loci was performed. (G) Naive CD4+ T cells from WT and RORtcreCxxc1fl/fl mice were differentiated into TH17 cells in the presence of TGF-1 and IL-6 for 24 hours, and H3K4me3 modifications at the indicated gene loci were detected by ChIP-qPCR. The statistical significance was determined by Students t test. Error bars show the means SD. *P 0.05, **P 0.01.

As shown in Fig. 4C, Cxxc1-binding sites were enriched at the center of CGIs, and about 31% of the Cxxc1-binding sites were found to colocalize with CGIs in TH17 cells (fig. S7A). We found that Cxxc1-dependent H3K4me3 modifications might be indispensable during TH17 differentiation (fig. S6); therefore, we carried out ChIP-seq analysis to map the genome-wide H3K4me3 modifications in TH17 cells. Similar to the locations of Cxxc1-binding sites, peaks indicating H3K4me3 modifications were also found mainly in gene promoters, and a reduction in the number of H3K4me3 peaks was found in Cxxc1-deficient TH17 cells (fig. S7B).

We mapped the genes with direct CXXC1 binding, genes with at least twofold difference of H3K4me3 modifications between WT and CXXC1 KO cells, and genes positively regulated by CXXC1 (at least twofold difference in gene expression between WT and KO cells). As shown in the Venn diagram (Fig. 4D), the loci of 1874 of 2346 (80%) genes with direct CXXC1 binding were associated with H3K4me3 changes, suggesting an important role of CXXC1 in mediating the histone modification of H3K4me3 in TH cells. Our data also identified 165 genes positively regulated by CXXC1 through positively changing the H3K4me3 modifications on their loci directly (Fig. 4D and table S1). On the other hand, we were able to identify more than 4000 genes whose expression was negatively regulated by CXXC1, although, in most of the cases, through indirect signaling pathways without directly affecting the H3K4me3 on their loci (fig. S7C). Together, our data suggest that CXXC1 plays a key role in regulating gene expressions through recruitment of H3K4me3 in TH cells.

ChIP-seq data showed that Cxxc1 bound upstream of or bound to the gene body of the Il6r, Il6st, Runx1, Satb1, Il21, Irf4, Rorc, Rora, and Batf gene loci was associated with a significant decrease in the H3K4me3 modification of the promoter regions of these genes in Cxxc1-deficient TH17 cells (Fig. 4E and fig. S7D). The direct binding of Cxxc1 in WT TH17 cells and the reduction in H3K4me3 modification in Cxxc1-deficient cells at these gene loci were confirmed by ChIP-PCR (Fig. 4, F and G, and fig. S7, E and F).

We then conducted 24-hour RNA-seq to determine potential key genes that are regulated by Cxxc1 at the early stage of differentiation and further confirmed the ChIP-seq results. We found that, even at the early stage, most of the key TH17 cellrelated transcripts (e.g., Il17a, Il17f, Il21, Il22, Il6ra, Il6st, Runx1, and Satb1) were significantly down-regulated in RORtcreCxxc1fl/fl TH17 cells and that the expression of key Treg cellrelated transcripts increased (e.g., Foxp3, Ccl3, Mgat5, Itgae, and Gpr83) (fig. S7G). We measured the expression of those genes by qPCR and obtained the same results as those obtained by 24-hour RNA-seq analysis (fig. S7H). In contrast to the 72-hour RNA-seq and qPCR results, we did not find a remarkable change in Rorc, Rora, or Irf4 expression at 24 hours. Although there are interactions between CXXC1 and loci of Rorc, Rora, and Irf4, these bindings only indicate enhanced accessibility of these loci. It still requires upstream TFs to promote the expression of Rorc, Rora, and IRF4. It may take 24 hours to open the gene locus, while it may take a longer time for essential TFs to promote their expression. Similar to the ChIP-seq results, we found a decline in Il6ra and Il6st (gp130), which organize the functional receptor for IL-6. The IL-6R subunit binds to IL-6 and the IL-6ST subunit, which are involved in signal transduction and play a vital role in TH17 cell differentiation (24).

We found that Il6r showed a significant decline in H3K4me3 modification levels and mRNA expression. Then, we detected the protein levels of IL-6R by flow cytometry and found a significant reduction in IL-6R in Cxxc1-deficient cells under TH17 cellpolarizing conditions (TGF-1 and IL-6) in different stages of differentiation (Fig. 5A). In addition, we found the same phenomenon in pathogenic TH17 cells (IL-1, IL-6, and IL-23), indicating that the reduction of IL-6R is independent of TGF- signaling (Fig. 5B). Moreover, we also detected a significant decline in IL-6R in dLckcre and ERT2cre deletion mice compared with that in WT mice (fig. S8A). Although IL-6ST expression was reduced at 24 hours, we found a moderate increase in IL-6ST expression at 72 hours (fig. S8B). IL-6R may be secreted in its soluble form, sIL-6R, which mediates the response by forming a complex with IL-6ST in a mechanism named trans-signaling (25). We therefore measured the level of sIL-6R in the supernatant by enzyme-linked immunosorbent assay (ELISA) and detected significantly lower levels of sIL-6R in Cxxc1-deficient cells than those in WT mice at all time points under TH17 cellpolarizing conditions (TGF-1 and IL-6) (Fig. 5C). These results indicated that IL-6R expression was significantly reduced in Cxxc1-deficient TH17 cells both in its membrane-bound and soluble forms.

(A and B) Naive CD4+ T cells (CD4+CD25-CD62LhiCD44lo) from RORtcreCxxc1fl/fl and WT mice were differentiated into TH17 cells with IL-6 and TGF-1 (A) or IL-1, IL-6, and IL-23 (B). The expression of IL-6R was measured by flow cytometry (left), and the mean fluorescence intensity (MFI) of IL-6R at different time points was measured (right). One of six experiments is shown. (C) Naive CD4+ T cells from RORtcreCxxc1fl/fl and WT mice were differentiated into TH17 cells with IL-6 and TGF-1, and the supernatants from cell cultures were collected at indicated time points. The amounts of IL-6R were then measured by ELISA. One of four experiments is shown. (D and E) Purified naive CD4+ T cells were stimulated for the indicated times with IL-6 (10 ng/ml). Phosphorylated and total STAT3 proteins were detected by Western blot assays (D) or flow cytometry (E). One of five experiments is shown. (F) Naive CD4+ T cells from WT and RORtcreCxxc1fl/fl mice were polarized into TH17 cells in the presence of TGF- and IL-6, and varying concentrations of IL-6R antibody were added. The expression levels of IL-17A and IL-17F were then analyzed by intracellular staining after 72 hours. One of six experiments is shown. (G and H) Naive CD4+ T cells from WT and RORtcreCxxc1fl/fl mice were cultured in the presence of TGF-1 and varying concentrations of IL-6 for 72 hours, and then, the expression levels of IL-17A, IL-17F, and Foxp3 were analyzed by intracellular staining after restimulation. One of seven experiments is shown. The statistical significance was determined by Students t test. Error bars show the means SD. *P 0.05, **P 0.01, ***P 0.001.

IL-6 signaling is required for the differentiation of TH17 cells, and the activation of STAT3 is a vital component of the TH17 cell induction mechanism (26). The significant reduction of IL-6R in RORtcreCxxc1fl/fl TH17 cells indicated that IL-6 signaling was possibly affected by the loss of Cxxc1 during TH17 differentiation. To assess this, we sorted RORtcreCxxc1wt/wt and RORtcreCxxc1fl/fl naive CD4+ T cells and stimulated them with IL-6 for different time periods, and then, we detected the activation of the downstream signaling protein STAT3. Both Western blot analysis and flow cytometry results showed a significant reduction in STAT3 activation in Cxxc1-deficient cells compared to that in WT cells stimulated with IL-6 (Fig. 5, D and E).

To further confirm the role of IL-6R defects in Cxxc1-deficient TH17 cells, we added different concentrations of IL-6R blocking antibody to TH17 culture medium in vitro. WT TH17 cells showed a marked reduction in differentiation when IL-6R blocking antibody was added, and the higher the concentration of IL-6R blocking antibody was, the lower the level of WT TH17 cell differentiation was. However, there was only a slight impact in Cxxc1-deficient TH17 cells compared with WT cells when IL-6R blocking antibody was added (Fig. 5F), further indicating the defects of IL-6R in Cxxc1-deficient TH17 cells.

IL-6 binds to IL-6R and is required for TH17 differentiation by activating STAT3 and inhibiting TGF-driven Foxp3 expression. The defects in IL-6R expression in TH17 cells may be compensated if the level of IL-6 is increased. To assess this, we polarized naive RORtcreCxxc1wt/wt or RORtcreCxxc1fl/fl CD4+ T cells into TH17 cells with varying levels of IL-6. Although IL-17 expression was only slightly restored with low and moderate levels of IL-6, it was restored with a high level of IL-6 (Fig. 5G). Moreover, IL-6 inhibited Foxp3 expression in RORtcreCxxc1fl/fl cells in a dose-dependent manner (Fig. 5H). These data suggest that Cxxc1 may regulate TH17 differentiation dependent on the IL-6/STAT3 pathway in the modulation of early signaling events downstream of the IL-6 receptor.

IL-21 or IL-6 alone or in combination with TGF- resulted in the up-regulation of the IL-23 receptor (IL-23R), RORt, and the TH17 cytokines. Our flow cytometry results showed no change in IL-21R expression, while the IL-23R expression was decreased in RORtcreCxxc1fl/fl TH17 cells (fig. S8C). The IL-6induced expression of IL-21, a process that is dependent on STAT3 and IL-21, serves as an autocrine factor that promotes and sustains TH17 lineage commitment (1, 7). IL-21, in synergy with TGF-, induced IL-17 expression independent of IL-6 and induced naive IL-6/ T cells into TH17 cells (6, 27). We then cultured naive CD4+ T cells in vitro with varying concentrations of IL-21 along with TGF-. Similar to the results observed upon the addition of varying levels of IL-6, IL-21 restored inconspicuous IL-17A and IL-17F expression at low and moderate levels, while it fully restored IL-17A and IL-17F expression in Cxxc1-deficient cells at high levels (fig. S8D). IL-23 promotes maintenance of the TH17 lineage and maintains the IL-17secreting phenotype, but it does not promote commitment to an IL-17secreting lineage. IL-23 could also induce IL-17A and IL-17F expression independent of IL-6 in conjunction with TGF- in naive CD4+ T cells (6). When naive CD4+ T cells were cultured in vitro with TGF- and varying concentrations of IL-23, defective IL-17A and IL-17F expression could not be restored, even at the highest level of IL-23, in Cxxc1-deficient cells (fig. S8E). In addition, to eliminate the residue effect of IL-6dependent signaling, we added IL-6R blocking antibody in these cultures and found consistent results (fig. S8, F and G).

As TGF- receptors are important for both TH17 and Treg cell differentiation, we detected the expression of TGF- receptors I and II. Protein levels of TGF- receptors I and II detected by flow cytometry analysis did not show a significant change in naive Cxxc1-deficient CD4+ T cells but showed an increase in Cxxc1-deficient TH17 cells compared with WT cells (fig. S9, A and B). Smad3 and Smad2 are downstream of TGF- signaling, and Smad2 positively regulates the generation of TH17 cells (28), while Smad3 promotes iTreg and inhibits TH17 cell differentiation (29). Western blot results showed no significant change in the Smad2 phosphorylation level (fig. S9C), while Smad3 showed a slight increase in phosphorylation (fig. S9D). Furthermore, the TCR activationinduced phosphorylation of both ERK and JNK proteins was also normal in Cxxc1-deficient cells (fig. S9E). These results indicated that Cxxc1-deficient TH17 cells transdifferentiated into Treg cells mainly due to IL-6/STAT3 signaling defects.

To further confirm IL-6R defects in Cxxc1-deficient TH17 cells, we overexpressed IL-6R in Cxxc1-deficient TH17 cells and carried out assays. We infected Cxxc1-deficient TH17 cells with retroviruses IL-6R or Cxxc1 complementary DNA as a positive control. The results showed that the overexpression of IL-6R potently increased the production of IL-17A and IL-17F relative to that in mock-transfected control Cxxc1-deficient TH17 cells (Fig. 6A). In addition, the overexpression of IL-6R could also efficiently reduce Foxp3 expression in Cxxc1-deficient TH17 cells (fig. S9F). Moreover, we found that the overexpression of Cxxc1 and the C-terminal domain of Cxxc1 (residues 361 to 656, C169A) increased the expression of IL-6R compared to that in mock-transfected Cxxc1-deficient TH17 cells, further confirming the regulation of IL-6R by Cxxc1 (Fig. 6B). We also overexpressed IL-6ST in Cxxc1-deficient TH17 cells and did not find the restoration of IL-17A and IL-17F production or the inhibition of Foxp3 expression compared with controls (Fig. 6A and fig. S9F).

(A) Naive CD4+ T cells from WT and RORtcreCxxc1fl/fl mice were differentiated into TH17 cells in the presence of TGF-1 and IL-6, and 20 to 24 hours, later the cells were transfected with the indicated retrovirus (Mock, Cxxc1, IL-6R, and IL-6ST). IL-17A and IL-17F levels were then measured by gated CD4+GFP+ cells after retrovirus infection for 72 hours. One of six experiments is shown. (B) Sorted naive CD4+ T cells were differentiated into TH17 cells in the presence of TGF-1 and IL-6, and 20 to 24 hours later, the cells were transfected with the indicated retrovirus. IL-6R levels were then measured by gated CD4+GFP+ cells after retrovirus infection for 72 hours. One of five experiments is shown. (C) Naive CD4+ T cells from WT and RORtcreCxxc1fl/fl mice were differentiated into TH17 cells in the presence of TGF-1 and IL-6, and 20 to 24 hours later, the cells were transfected with the indicated retrovirus [Mock, STAT3 (WT), STAT3 (A662C, N664C), and STAT3 (Y705A)]. IL-17A and IL-17F levels were then measured by gated CD4+GFP+ cells after retrovirus infection for 72 hours. One of five experiments is shown. (D) Naive CD4+ T cells from WT and RORtcreCxxc1fl/fl mice were differentiated into TH17 cells in the presence of TGF-1 and IL-6, and 20 to 24 hours later, the cells were transfected with the indicated retrovirus. CD4+GFP+ cells were then sorted after retrovirus infection for 72 hours and transferred into RAG1/ hosts. Two days later, the recipient mice were immunized with MOG3555 and FCA plus pertussis toxin to induce EAE. Clinical scores were recorded and calculated each day for the indicated times. Data are summed from three independent experiments. (E) IL-17A and IFN- production by CD4+ T cells isolated from CNS, draining lymph nodes, and spleens of Rag1/ mice at the peak of disease. One representative of three experiments is depicted. Error bars show the means SD. *P 0.05, **P 0.01, ***P 0.001 using the Students t test.

To further determine defects in the activation of STAT3, which is downstream of IL-6, we overexpressed STAT3 in Cxxc1-deficient TH17 cells. Our results showed that the overexpression of the active form of STAT3 (A662C, N664C) (30) strongly increased the production of IL-17A and IL-17F and inhibited Foxp3 expression relative to that in mock-transfected control Cxxc1-deficient TH17 cells, while the overexpression of WT STAT3 and the inactive form of STAT3 had almost no apparent effect (Fig. 6C and fig. S9G). However, we did not detect a change in IL-6R expression when the active form of STAT3 was overexpressed, indicating that IL-6R is upstream of STAT3 (fig. S9H). We also detected the reduced expression of RORt in Cxxc1-deficient TH17 cells, and RORt overexpression in Cxxc1-deficient TH17 cells partially rescued the TH17 differentiation defect under TH0 conditions and TH17-polarizing conditions (fig. S9I). Therefore, defects in STAT3 activation impaired RORt function at the Il17-Il17f locus.

Last, to better understand whether the overexpression of IL-6R in Cxxc1-deficient TH17 cells would affect the development of EAE in vivo, we sorted CD4+GFP+ T cells, transferred them into RAG1/ hosts, and then induced EAE with MOG3555. Mice that received WT TH17 cells developed the most severe disease, and mice that received Cxxc1-deficient TH17 cells overexpressing Cxxc1 or IL-6R developed more severe disease than those that received control Cxxc1-deficient TH17 cells (Fig. 6D). In addition, both the percentage and the number of TH17 cells in the CNS/draining lymph nodes/spleens of Rag1/ mice that received IL-6Roverexpressing TH17 cells were notably higher than those in the control mice (Fig. 6E). These data demonstrated that IL-6R could potently rescue the production of IL-17A in Cxxc1-deficient TH17 cells in vitro and in vivo and that Cxxc1 could restore IL-6R expression in Cxxc1-deficient TH17 cells.

Epigenetic regulation is an essential mechanism to coordinate T cell differentiation. Here, we report a crucial role of Cxxc1, which directly regulates promoter-associated H3K4me3 modification and the expression of genes such as Il6r that are essential for TH17 cell lineage specification. The transition of naive CD4 cells to TH17 cells in Cxxc1-deficient T cells was almost completely blocked, and the cells instead developed a Treg celllike transcriptional profile.

TH17 and Treg lineage differentiation is not only controlled by a combination of their specific cytokine milieus and TFs but also subjected to epigenetic control through various mechanisms. Previous work has shown that histones maintain TH17 cell differentiation and function by inducing histone modifications at the Il17a locus (31). The H3K4me3 methyltransferase MLL/menin/TrxG complex plays a critical role in the regulation of the TH2 cell program in murine and human systems (32). In addition, deletion of the H3K9me2 methyltransferase G9a also produces both TH17 and TH2 cell response defects (33). The conditional deletion of the H3K27me3 demethylases Jmjd3 and tripartite motif-containing 28 has been reported to have an inconsistent effect on the TH17 program, possibly due to different cellular environments (3437). However, our data showed that the loss of Cxxc1 led to a marked CD4+ T cell lineage switch from TH17 cells to Treg cells without affecting TH1 and TH2 cell differentiation. These data suggest that Cxxc1 is essential for TH17 cell differentiation and stability.

The functional receptor for IL-6 is composed of an IL-6R subunit that binds IL-6 and a gp130 subunit involved in signal transduction (38). The binding of IL-6 family of cytokines to their receptors activates STAT3, which is required for TH17 cell differentiation (26, 38). IL-6R is highly expressed in naive T cells and in the early phase of T cell activation, while IL-6R expression decreases in activated T cells. IL-6/gp130/STAT3 signaling is dominant in inhibiting the conversion of conventional T cells into Foxp3+ Treg cells in vivo, and in the absence of IL-6 signaling, almost no other cytokine can inhibit the conversion of T cells to Treg cells effectively (26). Our results showed a significant reduction in the IL-6R protein level in Cxxc1-deficient cells under TH17 cellpolarizing conditions (TGF-1 and IL-6) at different time points. Meanwhile, Cxxc1-deficient TH17 cells exhibited significantly defective TH17 differentiation and the strong expression of Foxp3 both in vitro and in vivo. ChIP-seq analysis revealed that Cxxc1 bound to and enhanced IL-6R by maintaining the appropriate H3K4me3 modification of its promoter regions. The cofactor that is bound by Cxxc1 and specifically enhances IL-6R expression in the early phase of TH17 cell differentiation remains to be elucidated in future studies.

Both the DNA methylation and H3K4me3 domains of Cxxc1 function in different cell types and tissues (1618). However, our overexpression assay indicated that the histone modification of Cxxc1 mostly functions in TH17 cell differentiation and stability. Our ChIP-seq data showed that Cxxc1 bound to TSS or gene body of several key genes involved in TH17 cell differentiation, including the Runx1, Satb1, IL21, Irf4, Rorc, and Rora gene loci, was associated with a significant decrease in the H3K4me3 modification of the promoter regions of these genes in Cxxc1-deficient TH17 cells. Although we suggested that IL-6R was the main target of Cxxc1 in TH17 cell differentiation, there are still some other target genes regulated by Cxxc1 that provide assistance in the TH17 cell differentiation process. In addition, our TH17 data illustrate that the cell typespecific binding profile of Cxxc1 may determine its primary function, which is consistent with our former analysis in thymocyte development and macrophage function.

In summary, we identified Cxxc1 to be a critical positive regulator of TH17 development at the early stage of differentiation, in which it positively regulates autoimmune disease and bactericidal activity mainly through promoting IL-6R expression and the subsequent activation of downstream pathways. Our findings provide insight into the association of epigenetic regulators with TH17 development and supply important clues for therapeutic approaches for the treatment of TH17-related inflammatory and autoimmune diseases.

The Cxxc1fl/fl mouse strain has been described previously (19). The ERT2cre mice were gifts from Y. W. He (Duke University Medical Center). The dLCKcre mice (JAX:012837) and IL-17AeGFP mice (018472 C57BL/6-IL-17atm1Bcgen/J) were from The Jackson Laboratories. The RORtcre mice (JAX: 022791) were gifts from J. Qiu (Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences). Rag1/ mice were purchased from The Jackson Laboratories. All experiments were performed with 6- to 10-week-old mice unless specified. All mice were kept in the Zhejiang University Laboratory Animal Center, and all animal experimental procedures were approved by the Animal Review Committee at Zhejiang University School of Medicine.

To induce EAE in Rag1/ mice, naive CD4+ T cells (CD4+CD25-CD62LhiCD44lo) from WT and RORtcreCxxc1fl/fl or dLckcreCxxc1fl/fl mice were sorted by the Mouse CD4 Nave T cell Enrichment Kit (no. 8804-6824-74, Invitrogen) and intravenously transferred into Rag1/ mice at 2 106 cells per mouse. Two days later, the recipient mice were subjected to EAE induction.

Female age-matched Rag1/ mice (8 to 10 weeks old) were immunized with an emulsion containing the MOG peptide MOG3555 (200 g per mouse; MEVGWYRSPFSRVVHLYRNGK; Sangon) in an equal amount of complete Freunds adjuvant (200 l per mouse; no. 7027, Chondrex Inc.). Pertussis toxin (200 ng per mouse; no. 181, List Biological Laboratories) was administered intravenously 0 and 2 days after induction. Clinical evaluation was performed daily using a five-point scale: 0, no clinical signs; 1, limp tail; 2, paraparesis (weakness, incomplete paralysis of one or two hind limbs); 3, paraplegia (complete paralysis of two hind limbs); 4, hind limb and fore limb paralysis; and 5, moribund or death.

Mice were intracardially perfused with 50 ml of phosphate-buffered saline (PBS). The forebrain and cerebellum were dissected, and spinal cords were collected from the spinal canal. CNS tissue was cut into pieces and digested with collagenase D (2 g/ml; Roche Diagnostics) and deoxyribonuclease I (DNase I; 1 g/ml; Sigma-Aldrich) at 37C for 20 to 30 min while rotating. Mononuclear cells were isolated by passing the tissue through a 200-mesh cell filter membrane, followed by 80%/40% Percoll gradient centrifugation. Mononuclear cells were carefully removed from the interface, washed with PBS, and resuspended in culture medium for further analysis. For cytokine analysis, mononuclear cells were stimulated for 5 hours with phorbol 12-myristate 13-acetate and ionomycin (both from Sigma-Aldrich) in the presence of brefeldin A (eBioscience) and then subjected to flow cytometry analysis to detect intracellular IL-17A, IFN-, and Foxp3.

RAG/ mice were provided with autoclaved water supplemented with antibiotics [ampicillin (1 g/liter), metronidazole (1 g/liter), neomycin (1 g/liter), and vancomycin (0.5 g/liter)] for 6 days and then provided with autoclaved water for 1 day. Then, naive CD4+ T cells (CD4+CD25-CD62LhiCD44lo) from WT and RORtcreCxxc1fl/fl mice were sorted and intravenously transferred into Rag1/ mice at 2 106 cells per mouse. Two days later, the recipient mice were subjected to C. rodentium infection as described (39). Briefly, mice were gavaged with 5 108 C. rodentium cells in 250 l of PBS per mouse. Bacteria were prepared by shaking at 37C overnight in LB broth, and then, the cultures were serially diluted and plated to measure the colony-forming units. Body weight was measured daily. Fecal pellets were collected, weighed, and then homogenized in sterile PBS, and C. rodentium colonies were identified on the basis of morphology after 18 to 24 hours of incubation at 37C on MacConkey agar plates.

To analyze CNS histology, mice were euthanized 22 days after EAE induction, and spinal cords were fixed in 4% paraformaldehyde and embedded in paraffin. Sections were cut and stained with Luxol fast blue and hematoxylin and eosin (H&E). To analyze colon histology, the colons from Rag1/ hosts 7 days after inoculation with C. rodentium were collected, treated as described above, and stained with H&E.

Mouse small intestines were dissected, and fat tissues and Peyers patches were removed. The intestines were cut open longitudinally and washed with Dulbeccos modified Eagles medium (DMEM) until no fecal pellets were observed. The intestines were then cut into approximately 5-mm-long pieces. The intestinal pieces were incubated in 37C prewarmed DMEM containing 3% fetal bovine serum (FBS), 20 mM Hepes, 5 mM EDTA, and dithiothreitol (0.15 mg/ml) for 10 min with constant agitation by droppers in a 37C water bath. The digested cells that were collected were intraepithelial lymphocytes. Then, the left small intestine was incubated in a solution of 3% FBS, 20 mM Hepes, DNase I (0.125 mg/ml), and collagenase II (0.5 mg/ml) in 37C prewarmed DMEM for 5 min with constant agitation by droppers in a 37C water bath, and the dissociated cells that were collected were LP lymphocytes. Last, the collected cells were isolated by passing the tissue through a 200-mesh cell filter membrane, followed by 80%/40% Percoll (GE Healthcare) gradient centrifugation. Cells were carefully removed from the interface, washed with PBS, and resuspended in culture medium for further analysis.

All flow cytometric data were collected on a FACS Calibur or FACS LSR II system (both from BD Biosciences) and analyzed using FlowJo analysis software v7.6.1. For intracellular cytokine staining, cells were stimulated for 5 hours at 37C with phorbol 12-myristate 13-acetate (50 ng/ml; Sigma), ionomycin (1 mg/ml; Sigma-Aldrich), and brefeldin A (eBioscience). After staining for surface markers, cells were fixed and permeabilized according to the manufacturers instructions (eBioscience). Intracellular staining was processed using intracellular fixation buffer (eBioscience), and a TF staining buffer set (eBioscience) was used for RORt and Foxp3 staining. For the detection of phosphorylated STAT3 by flow cytometry, BD Phosflow Fix Buffer I and Perm/Wash Buffer I were used.

The following antibodies (clone names are in parentheses) with different fluorochrome labels were purchased from eBioscience: CD4 (RM4-5), CD8a (53-6.7), TCR (H57-597), CD44 (IM7), CD62L (MEL-14), IFN- (XMG1.2), IL-17A (TC11-18H10.1), IL-4 (11B11), and RORt (B2D). The following reagents were purchased from BioLegend: IL-23R (12B2B64), IL-21R (4A9), CD126 (D7715A7), Foxp3 (MF-14), and IL-17F (9D3.1C8).

For Western blot and ChIP, anti-Cxxc1 (1:1000 dilution for Western blot; 6 g for each immunoprecipitation and ChIP reaction; ab56035) was purchased from Abcam. H3K4me3 (4 g for each ChIP reaction; 39915) was purchased from Active Motif. AntipC-SMAD2 (3101), anti-SMAD2 (3103), anti-SMAD3 (9523), antipC-SMAD3 (9520), anti-STAT3 (Tyr705) (9131), anti-STAT3 (9132), anti-Erk (Thr202/Tyr204) (4370), anti-Erk (4695), anti-JNK (T183/Y185) (9251), and anti-JNK (9258) were obtained from Cell Signaling Technology.

Naive CD4+ T cells (CD4+CD25CD62LhiCD44lo) were purified by a FACS Aria II flow cytometer or sorted by the Mouse CD4 Nave T cell Enrichment Kit (no. 8804-6824-74, Invitrogen). Naive CD4+T cells were cultured with irradiated (30 Gy) anaphase-promoting complex sorted from spleen at a ratio of 1:3 and were activated with anti-CD3 (2 g/ml) and anti-CD28 (3 g/ml) in a 48-well plate (5 105 T cells per well). T cells were cultured in RPMI 1640 medium supplemented with 10% FBS, sodium pyruvate, penicillin-streptomycin, and 2-mercaptoethanol.

For nonpathogenic TH17 cell differentiation, culture medium was supplemented with IL-6 (20 ng/ml), TGF-1 (5 ng/ml), antiIL-4 (10 ng/ml), antiIL-12 (10 ng/ml), and antiIFN- (10 ng/ml). For pathogenic TH17 cells differentiation, culture medium was supplemented with IL-1 (20 ng/ml), IL-6 (20 ng/ml), and IL-23 (20 ng/ml), antiIL-4 (10 ng/ml), antiIL-12 (10 ng/ml), and antiIFN- (10 ng/ml). Other T cell differentiation were performed: TH1, IL-12 (20 ng/ml) and antiIL-4 (10 mg/ml); TH2, IL-4 (50 ng/ml), antiIFN- (10 ng/ml), and antiIL-12 (10 mg/ml); iTreg cells, TGF-1 (5 ng/ml), antiIL-4 (10 ng/ml), antiIL-12 (10 ng/ml), and antiIFN- (10 ng/ml). Neutralizing antiIFN- (XMG1.2), antiIL-4 (11B11), and antiIL-12 (C17.8) were from BioLegend.

Retroviruses were produced in Plat-E cells. Plat-E cells were transfected with pMX-IRES-GFP plasmids containing the indicated genes, and the medium was replaced twice with 3 ml of fresh medium every 10 hours after transfection. The retrovirus-containing supernatant was collected 72 hours after the medium was replaced for the second time and used to infect T cells.

Sorted naive CD4+ T cells were differentiated into TH17 cells in the presence of TGF-1 and IL-6 (48-well plate, 0.5 106 cells per well); 20 to 24 hours later, the cells were transfected with 1 ml of the indicated retrovirus in the presence of polybrene (10 g/ml) and 10 mM Hepes and infected for 2 hours at 1500g at 32C. After transfection, the cells were resuspended in TH17 differentiation medium and cultured for 3 days. The indicated cytokines (e.g., IL-17A and IL-17F) and other TFs (e.g., Foxp3 and RORt) were measured by gated CD4+GFP+ cells after retrovirus infection for 72 hours.

For RNA-seq, total RNA was extracted from naive CD4+ T cells differentiated in the presence of TGF-1 (5 ng/ml) and IL-6 (20 ng/ml) for 24 or 72 hours using the RNeasy kit (Qiagen). Library construction and sequencing were performed on a BGISEQ-500 platform by the Wuhan Genomic Institution (www.genomics.org.cn; BGI, Shenzhen, China). All reads were mapped to the mm10 mouse genome, and the uniquely mapped reads were subjected to RNA-seq data analysis using the Hierarchical Indexing for Spliced Alignment of Transcripts system (40).

ChIP assays were performed according to the manufacturers instructions with modifications using the ChIP-IT kit (Active Motif, USA). Briefly, the TH17 cells were fixed with 1% formaldehyde, and then, the cross-linked chromatin was sonicated in a 4C water bath using a Bioruptor Pico sonicator (Diagenode) to obtain DNA fragments between 150 and 500 base pairs (bp) in size. For Cxxc1 ChIP-seq, 5 106 TH17 of cells and 6 g of Cxxc1 antibody were used for each sample. For H3K4me3 ChIP-seq, 3 106 of TH17 cells and 4 g of H3K4me3 antibody were used for each sample.

The immunoprecipitated DNA was purified and subjected to sequencing library preparation using a VAHTSTM Universal DNA Library Prep Kit for Illumina V2 (Vazyme Biotech Co. Ltd.) according to the manufacturers protocol. The DNA libraries were then sequenced with an Illumina HiSeq X Ten system at Veritas Genetics in Hangzhou.

Sequenced reads of 150 bp were obtained using the CASAVA 1.8.2 package (Illumina). All reads were mapped to the mm10 mouse genome, and uniquely mapped reads were subjected to a further peak identification process. MACS2_V2.1.1 was used to identify significant peaks (q = 0.05) with both input DNA and ChIP DNA in Cxxc1-deficient cells as controls. The output of the peak files was converted by IGV browser. To calculate the tag density for Cxxc1-binding sites or H3K4me3 modifications around the TSS or at the centers of CGIs, uniquely mapped tags were summarized in 100-bp windows, and all window tag counts were normalized by the total number of bases in the windows and the total read number for the given sample.

Statistical analyses were performed using GraphPad Prism (GraphPad Software). The statistical significance was determined by Students t test. All error bars shown in this article represent SDs. Significance levels (P values) are presented in the figures.

Acknowledgments: We thank X. L. Liu (Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences) for gifts of cell lines; J. Qiu (Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences) for providing C. rodentium and mice; L. Shen (Zhejiang University) for helping with ChIP-seq data analysis; H. Y. Fang (Zhejiang University) for providing reagents; and L. R. Lu and D. Wang for their helpful discussion. We thank Y. Y. Huang, Y. W. Li, and J. J. Wang (Zhejiang University) for helping with the cell sorting; Y. Zhang and R. Ma (Zhejiang University) for feeding the mice. Funding: This work was supported, in part, by grants from the National Basic Research Program of China 973 Program (2015CB943301), the National Natural Science Foundation of China (81830006, 31670887, 31870874, and 31800734), Zhejiang Provincial Key Project of Research and Development (2019C03043), the Zhejiang Natural Science Foundation (LQ16H030003), and the Zhejiang Science and Technology Program(2017C37117 and 2017C37170). Author contributions: L.Wa. and F.L. designed the research. F.L., X.M., Y.G., W.C., Q.X., Z.H., W.L., J.C., S.H., and X.Z. performed the experiments and data analysis. L.Wa. and F.L. wrote the manuscript. L.L., C.W., J.W., W.Q., L.We., and D.W. provided expertise and advice. L.We. and L.Wa. supervised the project. Competing interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. The ChIP-seq and RNA-seq datasets were deposited in the GSE accession:GSE132208 and the SRA accession: PRJNA545626. Additional data related to this paper may be requested from the authors.

Excerpt from:
Epigenetic initiation of the TH17 differentiation program is promoted by Cxxc finger protein 1 - Science Advances